Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
Kaleido Biosciences (Nasdaq: KLDO) announced CEO Dan Menichella will participate in a fireside chat at the Morgan Stanley 19th Annual Virtual Global Healthcare Conference on September 9 at 2:45 PM ET. This event emphasizes Kaleido's innovative, chemistry-driven approach to microbiome health, focusing on developing Microbiome Metabolic Therapies (MMT™) to address significant patient needs. A webcast of the presentation will be available on their website, with an archived replay for 90 days post-event.
- None.
- None.
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in a fireside chat at the Morgan Stanley 19th Annual Virtual Global Healthcare Conference at 2:45PM ET on Thursday, September 9.
The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 90 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors and Media
Kotaro Yoshida
Argot Partners
212-600-1902
kaleido@argotpartners.com
FAQ
When is Kaleido Biosciences' CEO participating in the Morgan Stanley Healthcare Conference?
Where can I watch the Kaleido Biosciences conference presentation?
What is the focus of Kaleido Biosciences' research?
How long will the Kaleido Biosciences conference presentation be available?
What stock symbol is associated with Kaleido Biosciences?
